PulseSight Therapeutics
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2-10 Rue D'oradour-sur-glane, Paris, Ile...Phone Number
+33 184791060Website
www.pulsesight.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About PulseSight Therapeutics
PulseSight Therapeutics is advancing an exciting pipeline of novel non-viral minimally-invasive gene therapies designed to address still unmet need for treatments against severe retinal diseases leading to blindness, with a focus on age-related macular degeneration (AMD) including wet AMD and late stage dry AMD/Geographic atrophy (GA).Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is PulseSight Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
PulseSight Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on PulseSight Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once PulseSight Therapeutics has new funding data
Click to see if PulseSight Therapeutics had a recent Job posting/layoffs
Check out if PulseSight Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at PulseSight Therapeutics
Product Launch: Get notified when PulseSight Therapeutics launches new products
Check if PulseSight Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined PulseSight Therapeutics as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
PulseSight Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
PulseSight Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about PulseSight Therapeutics.
PulseSight Therapeutics Tech Stack
A closer look at the technologies used by PulseSight Therapeutics
See more technologies
PulseSight Therapeutics News & Media
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present new data on iron dysregulation and ferroptosis role in age related macular degeneration (AMD) during an oral presentation at 25th EURETINA Congress1, the major ophthalmology conference being held in Paris this week 4-7 September.PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
PARIS, Feb. 13, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its Series A financing with existing investor Pureos BioVentures committing new funds to support the Phase I study of PST-611 and enable preparation for a Phase IIa clinical trial.PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy
PARIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical Trial Authorization (CTA) to Agence Nationale de Sécurité du Médicament et des produits de santé (ANSM) for a Phase I trial (PST-611-CT1) assessing the safety and tolerability of PST-611 in humans.PulseSight Therapeutics Presents New Data on PST-611 Transferrin Vectorized Therapy for Geographic Atrophy at EVER Congress 2024
PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead program PST-611, a DNA plasmid expressing human transferrin, in dry age-related macular degeneration (AMD)/geographic atrophy (GA) at the European Association for Vision and Eye Research 27th EVER Congress 2024.
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding PulseSight Therapeutics
Sign Up For FreeTo access detailed company insights
PulseSight Therapeutics is advancing an exciting pipeline of novel non-viral minimally-invasive gene therapies designed to address still unmet need for treatments against severe retinal diseases leading to blindness, with a focus on age-related macular degeneration (AMD) including wet AMD and late stage dry AMD/Geographic atrophy (GA).... Read More
